CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 18:48:23 27/06/2024 BST | ||
| 4.67 EUR | +10.40% |
|
| Current month | +5.18% | ||
| 1 month | +22.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 4.67 | +10.40% |
| 26/06/24 | 4.23 | -2.31% |
| 25/06/24 | 4.33 | -6.28% |
| 24/06/24 | 4.62 | +6.45% |
| 21/06/24 | 4.34 | -4.41% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 06:48 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX8LN9 |
| ISIN | DE000VX8LN96 |
| Date issued | 11/03/2022 |
| Strike | 180.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.98 € |
|---|---|
| Lowest since issue | 1.36 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
228.7
USD
Average target price
283.2
USD
Spread / Average Target
+23.80%
- Stock Market
- Certificates
- Certificat
